Literature DB >> 9247365

The 677C-->T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease.

P Verhoef1, F J Kok, L A Kluijtmans, H J Blom, H Refsum, P M Ueland, D A Kruyssen.   

Abstract

Homozygosity for a 677C-->T mutation at the locus that codes for 5,10-methylenetetrahydrofolate reductase (MTHFR), a folate-dependent crucial enzyme in homocysteine metabolism, may render the enzyme thermolabile and less active and has been associated with increased levels of plasma total homocysteine (tHcy). We assessed whether this mutation was associated with increased risk of coronary atherosclerosis and plasma levels of tHcy and furthermore studied whether folate status would modify the associations. Data were collected from subjects with substantial coronary atherosclerosis (> or = 90% occlusion in one and > or = 40% occlusion in a second coronary artery, referred to as cases, n = 131) or virtually no coronary narrowing (referred to as coronary controls, n = 87) and from a population-based control group (n = 100), all residing in the Rotterdam area, The Netherlands. Both males and females, aged 25-65 years were studied. The frequency of homozygosity for the mutation (+/+) in cases (10.0%) did not significantly differ statistically from that observed in coronary controls (11.5%, P = 0.71), population-based controls (7.0%, P = 0.43), or combined control groups (9.1%, P = 0.80). In the overall group (as well as in the three subgroups), plasma tHcy levels, fasting and to a lesser extent after a methionine-loading test, were higher in +/+ subjects than in homozygous normal subjects (-/-), whereas heterozygous subjects (+/-) had intermediate levels (Ptrend = 0.001). The +/+ subjects with erythrocyte folate levels < 790 nmol/l (population median) had a 77%, (95% CI, 27-144%) higher geometric mean fasting tHcy (21.4, micromol/l) than those with higher erythrocyte folate (12.1 micromol/l). The odds ratio (OR) of coronary atherosclerosis for +/+ subjects, with +/- and -/- subjects as the reference group, in analyses with combined control groups, was 1.1 (95% CI, 0.5-2.4). The ORs were 2.2 (95% CI, 0.7-6.8) and 0.6 (95% CI, 0.2-1.7) among subjects with low and high folate levels, respectively. Our study indicates that homozygosity for the 677C-->T MTHFR mutation, especially in combination with low folate status, predisposes to high plasma levels of fasting tHcy. However, homozygosity for this mutation, whether or not in combination with low folate status, was not associated with increased risk of coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247365     DOI: 10.1016/s0021-9150(97)00084-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  12 in total

1.  Methylenetetrahydrofolate reductase gene polymorphism, homocysteine and risk of macroangiopathy in Type 2 diabetes mellitus.

Authors:  J Sun; Y Xu; Y Zhu; H Lu
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

2.  Hyperhomocyst(e)inaemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy.

Authors:  M Weger; O Stanger; H Deutschmann; M Simon; W Renner; O Schmut; J Semmelrock; A Haas
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

3.  Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care.

Authors:  G L Booth; E E Wang
Journal:  CMAJ       Date:  2000-07-11       Impact factor: 8.262

4.  A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status.

Authors:  Simonetta Friso; Sang-Woon Choi; Domenico Girelli; Joel B Mason; Gregory G Dolnikowski; Pamela J Bagley; Oliviero Olivieri; Paul F Jacques; Irwin H Rosenberg; Roberto Corrocher; Jacob Selhub
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

5.  MTHFR 677 CT/MTHFR 1298 CC genotypes are associated with increased risk of hypertension in Indians.

Authors:  Suchita Markan; Meenakshi Sachdeva; Badan Singh Sehrawat; Savita Kumari; Sanjay Jain; Madhu Khullar
Journal:  Mol Cell Biochem       Date:  2007-03-01       Impact factor: 3.396

6.  Lack of association of methylenetetrahydrofolate reductase 677C>T mutation with coronary artery disease in a Pakistani population.

Authors:  M Perwaiz Iqbal; Tasneem Fatima; Siddiqa Parveen; Farzana A Yousuf; Majid Shafiq; Naseema Mehboobali; Abrar H Khan; Iqbal Azam; Philippe M Frossard
Journal:  J Mol Genet Med       Date:  2005-07-28

7.  Methylenetetrahydrofolate reductase TT genotype as a predictor of cardiovascular risk in hypertensive adolescents.

Authors:  Hee Sun Koo; Hee Sook Lee; Young Mi Hong
Journal:  Pediatr Cardiol       Date:  2007-10-05       Impact factor: 1.655

8.  A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells.

Authors:  P J Bagley; J Selhub
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

9.  The methylenetetrahydrofolate reductase C677T mutation induces cell-specific changes in genomic DNA methylation and uracil misincorporation: a possible molecular basis for the site-specific cancer risk modification.

Authors:  Kyoung-Jin Sohn; Hyeran Jang; Mihaela Campan; Daniel J Weisenberger; Jeffrey Dickhout; Yi-Cheng Wang; Robert C Cho; Zoe Yates; Mark Lucock; En-Pei Chiang; Richard C Austin; Sang-Woon Choi; Peter W Laird; Young-In Kim
Journal:  Int J Cancer       Date:  2009-05-01       Impact factor: 7.396

10.  B-vitamins, homocysteine and gene polymorphism in adults with fasting or post-methionine loading hyperhomocysteinemia.

Authors:  Chien-Hsiung Cheng; Yi-Chia Huang; Feng-Pan Chen; Ming-Chih Chou; Tsung-Po Tsai
Journal:  Eur J Nutr       Date:  2008-10-31       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.